Effects of Sildenafil on Choroidal Thickness in AMD

Status Terminated

Clinical Trial Summary

Choroidal thinning has been hypothesized to partake in the pathogenesis of age-related macular degeneration (AMD), but it is not known if increasing choroidal thickness may potentially alter the disease course. Past studies have shown that a single dose of the phosphodiesterase type-5 inhibitor sildenafil citrate can increase choroidal thickness in young healthy patients. The investigators hypothesize that sildenafil may also increase choroidal thickness in eyes with AMD and perhaps potentially reduce AMD progression. Alternatively, if sildenafil has minimal effect on choroidal thickness in eyes in patients with AMD, such results may suggest that choroidal vascular compliance or stiffness is reduced in this condition. Patients seen at the Duke Eye Center with a diagnosis of AMD or age-matched control subjects with no macular pathology will be administered a single 100mg oral dose of sildenafil citrate (Viagra®; Pfizer), and undergo EDI-OCT imaging before and after treatment. Images obtained will be used to measure choroidal thickness, as well as central macular thickness (CMT) and macular volume (MV). Choroidal thickness changes after a single-dose sildenafil treatment in AMD patients will be compared with age-matched control subjects using standard statistical methods. By also correlating choroidal thickness changes with functional (visual acuity) and anatomical (CMT & MV) changes, the investigators hope to further their understanding of the choroid's role in aging and AMD pathogenesis. The safety of a single dose of sildenafil citrate will be addressed by excluding any patients with risk factors or using medications that are contraindicated for sildenafil as determined by careful informed consent and a study questionnaire.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01830790
Study type	Interventional
Source	Duke University
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2013
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05984927` - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration	Phase 1/Phase 2
Active, not recruiting	`NCT05536297` - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy	Phase 3
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Completed	`NCT04005352` - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)	Phase 3
Withdrawn	`NCT02873351` - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	Phase 2
Active, not recruiting	`NCT02802657` - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration	Phase 4
Not yet recruiting	`NCT02864472` - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose	Phase 4
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT01445548` - Sirolimus for Advanced Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT02035722` - Intravitreal Injections-related Anxiety	Phase 2/Phase 3
Completed	`NCT01175395` - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)	Phase 1/Phase 2
Recruiting	`NCT01048476` - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration	Phase 1/Phase 2
Active, not recruiting	`NCT01174407` - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration	N/A
Terminated	`NCT00712491` - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00345176` - Age-Related Eye Disease Study 2 (AREDS2)	Phase 3
Completed	`NCT02140151` - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT02555306` - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT04796545` - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration	N/A
Completed	`NCT03166202` - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed	`NCT01397409` - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)	Phase 2